FROSTY FUTURES
NOVEMBER 11, 2005
INDICES
Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting
--------------------------------------------------------------------------------
Wed Nov 09 09:16:51 2005 EST
CAMBRIDGE, Mass., Nov. 9, 2005 (Canada NewsWire via COMTEX) --
Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday,
November 11, 2005 at 9:00 a.m. EST. During the call, the Company will review
results from the Phase Ib study of its investigational oral hepatitis C
protease inhibitor, VX-950, that will be presented while attending the 56th
American Association for the Study of Liver Diseases (AASLD) Annual Meeting.
The meeting is being held in San Francisco, CA from November 11-15, 2005.
The webcast will be available to all interested parties through Vertex's
website, http://www.vrtx.com, and will be archived on the Company's website
until November 25, 2005. To access the webcast, go to the investor center and
select 'conference calls.' To ensure a timely connection, it is recommended
that users register at least 15 minutes prior to the scheduled webcast.
Vertex is also providing a podcast MP3 file available for download on the
Vertex website, http://www.vrtx.com, until November 25, 2005.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes
the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Contact:
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE: Vertex Pharmaceuticals Incorporated
Lora Pike, Manager, Investor Relations of Vertex Pharmaceuticals Incorporated,
+1-617-444-6755
Copyright (C) 2005 CNW Group. All rights reserved.
**********************************************************************
As of Saturday, 11-05-2005 23:59, the latest Comtex SmarTrend(SM) Alert,
an automated pattern recognition system, indicated an UPTREND on
06-17-2005 for VRTX @ $14.69.
(C) 2005 Comtex News Network, Inc. All rights reserved.
--------------------------------------------------------------------------------
VRTX,
MA-Vertex-AASLD-mtng, BIOTECHNOLOGY, BUSINESS, cnw, financenews, financenews+select, HEALTHCARE, PHARMACEUTICALS, PUBCO+SELECT, PUBLIC+COMPANIES, WALL+STREET,
**StorySrvr-H-03(WEBSTORY-B-03)(CNW313c4246
CONTACT ME: williamfrost@comcast.net or call 615 331 8567.
TO SUBSCRIBE: www.frostyfutures.com.
Trading futures is for individuals willing to assume greater risk for the opportunity of greater rewards. Only speculative capital should be used. Past performance is no assurance of future profits. Information contained herein is believed reliable but original sources of data have not been independently verified therefore is not guaranteed. Ideas and suggestions are just that. Nothing herein should be construed to be a solicitation to trade futures or options. Hedgers should have a defined plan.
